TWI280133B - Process for preparing C-7 substituted steroids - Google Patents
Process for preparing C-7 substituted steroids Download PDFInfo
- Publication number
- TWI280133B TWI280133B TW092106330A TW92106330A TWI280133B TW I280133 B TWI280133 B TW I280133B TW 092106330 A TW092106330 A TW 092106330A TW 92106330 A TW92106330 A TW 92106330A TW I280133 B TWI280133 B TW I280133B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- compound
- produce
- doc
- acid
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- -1 steroid compounds Chemical class 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000011968 lewis acid catalyst Substances 0.000 claims abstract description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 30
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 15
- 229960001208 eplerenone Drugs 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000012038 nucleophile Substances 0.000 claims description 9
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000002841 Lewis acid Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000007517 lewis acids Chemical class 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 150000002596 lactones Chemical class 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 150000007530 organic bases Chemical group 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000000052 vinegar Substances 0.000 claims description 2
- 235000021419 vinegar Nutrition 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 claims 1
- 241000239290 Araneae Species 0.000 claims 1
- 101150047265 COR2 gene Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims 1
- 229930004069 diterpene Natural products 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 238000002309 gasification Methods 0.000 claims 1
- 229910052703 rhodium Inorganic materials 0.000 claims 1
- 239000010948 rhodium Substances 0.000 claims 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000012434 nucleophilic reagent Substances 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 239000000203 mixture Substances 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000002609 medium Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 238000011081 inoculation Methods 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 20
- 239000012499 inoculation medium Substances 0.000 description 19
- 230000036983 biotransformation Effects 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002002 slurry Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000000855 fermentation Methods 0.000 description 13
- 230000004151 fermentation Effects 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000001223 reverse osmosis Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000013405 beer Nutrition 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000013530 defoamer Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 4
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 4
- VZAWCLCJGSBATP-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundecane Chemical compound C1CCCCCCCCCC1N1NCCCCCCCCC1 VZAWCLCJGSBATP-UHFFFAOYSA-N 0.000 description 3
- FJSKXQVRKZTKSI-UHFFFAOYSA-N 2,3-dimethylfuran Chemical compound CC=1C=COC=1C FJSKXQVRKZTKSI-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- KCESDDJHDQBIHN-UHFFFAOYSA-N SC=1OC=CC=1S Chemical compound SC=1OC=CC=1S KCESDDJHDQBIHN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005937 allylation reaction Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002098 polyfluorene Polymers 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 3
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000190144 Lasiodiplodia theobromae Species 0.000 description 2
- 229910019093 NaOCl Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002535 acidifier Substances 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- PHSMPGGNMIPKTH-UHFFFAOYSA-K cerium(3+);trifluoromethanesulfonate Chemical compound [Ce+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F PHSMPGGNMIPKTH-UHFFFAOYSA-K 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- SYHPANJAVIEQQL-UHFFFAOYSA-N dicarboxy carbonate Chemical compound OC(=O)OC(=O)OC(O)=O SYHPANJAVIEQQL-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- MDHIWBNJNHUBJL-VMXHOPILSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC=C21 MDHIWBNJNHUBJL-VMXHOPILSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- PUNXVEAWLAVABA-UHFFFAOYSA-N 1,2,3,4-tetrahydroanthracene;1,2,5,6-tetrahydroanthracene Chemical compound C1=CC=C2C=C(CCCC3)C3=CC2=C1.C1=CCCC2=C1C=C1CCC=CC1=C2 PUNXVEAWLAVABA-UHFFFAOYSA-N 0.000 description 1
- JCMVPOVHKWWBAU-UHFFFAOYSA-N 1,2-dichlorohydrazine Chemical compound ClNNCl JCMVPOVHKWWBAU-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- RKVSFMBPCREZAM-UHFFFAOYSA-N 2,3-dimethyltridec-2-ene Chemical compound CCCCCCCCCCC(C)=C(C)C RKVSFMBPCREZAM-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HRADVHZVMOMEPU-UHFFFAOYSA-N 3-iodopyrrolidine-2,5-dione Chemical compound IC1CC(=O)NC1=O HRADVHZVMOMEPU-UHFFFAOYSA-N 0.000 description 1
- TXWNPSBZSLYRNE-UHFFFAOYSA-N 5-methyl-2-(3-methylbutyl)hexan-1-amine Chemical compound CC(C)CCC(CN)CCC(C)C TXWNPSBZSLYRNE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000122824 Aspergillus ochraceus Species 0.000 description 1
- KNRKLOGFJUUBMJ-UHFFFAOYSA-N CC(CCCCCCCCC)(C)C.C=C Chemical compound CC(CCCCCCCCC)(C)C.C=C KNRKLOGFJUUBMJ-UHFFFAOYSA-N 0.000 description 1
- UDODQZLHXZBDJC-UHFFFAOYSA-N CC(CCCCCCCCCC#N)(C)C Chemical compound CC(CCCCCCCCCC#N)(C)C UDODQZLHXZBDJC-UHFFFAOYSA-N 0.000 description 1
- MSPJFCGXTICBEG-UHFFFAOYSA-N CCCCCCCCCC(C)(C)C.Cl Chemical compound CCCCCCCCCC(C)(C)C.Cl MSPJFCGXTICBEG-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- YYLLIJHXUHJATK-UHFFFAOYSA-N Cyclohexyl acetate Chemical compound CC(=O)OC1CCCCC1 YYLLIJHXUHJATK-UHFFFAOYSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- MMVYPOCJESWGTC-UHFFFAOYSA-N Molybdenum(2+) Chemical class [Mo+2] MMVYPOCJESWGTC-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- RKZYTKNOUUDGMS-UHFFFAOYSA-L S(O)(O)(=O)=O.O.O.O.O.O.[OH-].[Ba+2].[OH-] Chemical compound S(O)(O)(=O)=O.O.O.O.O.O.[OH-].[Ba+2].[OH-] RKZYTKNOUUDGMS-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 1
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
- ISCRJJYYJRWMDG-UHFFFAOYSA-N [Ru].C(CCCCCCCC=C/CCCCCCCC)(=O)O Chemical compound [Ru].C(CCCCCCCC=C/CCCCCCCC)(=O)O ISCRJJYYJRWMDG-UHFFFAOYSA-N 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000004808 allyl alcohols Chemical class 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- 238000005097 cold rolling Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- ZEFHIVBQGCPPHS-UHFFFAOYSA-N dichloromethane;hydrazine Chemical compound NN.ClCCl ZEFHIVBQGCPPHS-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 238000007037 hydroformylation reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- CNLIZIJWOMRBLD-UHFFFAOYSA-N n,n-dimethylpyridin-1-ium-1-amine Chemical compound CN(C)[N+]1=CC=CC=C1 CNLIZIJWOMRBLD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000020573 organic concentrate Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- WLHPCEJPGLYEJZ-UHFFFAOYSA-N prop-2-enyltin Chemical compound [Sn]CC=C WLHPCEJPGLYEJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- SYBXSZMNKDOUCA-UHFFFAOYSA-J rhodium(2+);tetraacetate Chemical compound [Rh+2].[Rh+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O SYBXSZMNKDOUCA-UHFFFAOYSA-J 0.000 description 1
- OJLCQGGSMYKWEK-UHFFFAOYSA-K ruthenium(3+);triacetate Chemical compound [Ru+3].CC([O-])=O.CC([O-])=O.CC([O-])=O OJLCQGGSMYKWEK-UHFFFAOYSA-K 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- BHAROVLESINHSM-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1.CC1=CC=CC=C1 BHAROVLESINHSM-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- SZKKNEOUHLFYNA-UHFFFAOYSA-N undecanenitrile Chemical compound CCCCCCCCCCC#N SZKKNEOUHLFYNA-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Description
1280133 玫、發明說明: 技術領域 某些特定的C-7經取代類固醇,例如:依普利酮 (eplerenone),因其酸固酮對抗劑活性而已為吾人所熟知並 因此對於循環系統疾病的治療和預防很有用。Eplerenone是 數個專利和申請案,如:美國專利號4,559,332和5,981,744 及國際公告案WO 98/25948及WO 97/21720之主題。然而, 由於eplerenone具有更新且更廣泛的臨床用途,因此有必要 改善這個類固醇和其他相關類固醇的製造方法。對於 eplerenone和其他相關類固醇化合物之有效合成的一個主要 障礙就是在C-7位置上導入羧基或可能轉換成羧基之官能 基。 先前技術 烯丙衍生物,特別是烯丙基醋酸酯、苯甲酸酯、三甲基 乙酸酯及其類似物,已為吾人所知在一路易士酸之影響下 可和親核劑反應,此方法如前所述稱為烯丙化反應。烯丙 化反應已經應用在很多受質上,例如,glycals已顯示可藉 缔丙化反應產生烯丙基糖苷、氰化糖嘗和疊氮糖(glycosal azide) (Yadav,J. S·,et· al·,Tetrahedron Lett·,2001,42, 4057.)。烯丙基醋酸醋和碳酸酯可產生對應之氰化物 (Yasushi,T·,et· al·,J· Org. Chem·,1993,58,16)。多電子芳 基和雜芳族可產生對應之晞丙化產物(Maikov, A. V·,et. al·, J. Org. Chem·,1999, 64, 2751)。然而烯丙化反應,並未應用 至類固醇以產生有利於轉變成7-羧基取代類固醇例如依普 84103-950628.doc 1280133 利酮之7-取代類固醇。3,17麵二乙酿氧·7·經雄固燒士缔,或 對應乏7-甲烷磺酸酯,已經利用粗觸媒氯化鋁與酚和甲氧 苯反應(Negi,A· S·,et. al” Steroids,1995, 60, 470)。此結果 物7-芳基衍生物則以c_7表異構物之混合物在低產量下產 生。進而,要將此7-芳基衍生物使用在7_羧基取代類固醇之 製備上將有困難。 發明内究 本發明係關於一種製備化學式I之新穎7_羧基取代類固醇 化合物之方法,
化學式I 其中1^是11或一C0R2 ; R2是cvc6燒基或是匕-匕燒氧基; O-Rj 4是(:112或一卜,此中的〇113呈〇;組態; R3^h^-cor2 ; z2是-CH-;或 4和Z2之間可能形成碳-硬雙键; Q是 >〇,
〇 0H.
OH
OH 或 1-6;^ " Υ是-CN,-CH2_CH=CH2完基 /{〇> 84103-950628.doc 1280133 CHR4C(0)Ar , CHIUC^COCu 烷基、CHR4C(〇)XAr 或 CHhC^C^XCu烷基; 其中RfOC^烷基或芳基 x=o 或 s 此等新穎中間產物在製備7-羧基取代類固醇化合物時很 有用,而且特別的是,本發明是製備9,11α -環氧q7a •羥 基-3-氧娠-4-烯-7α -21·二羧酸、r •内酯、甲基醚(依普利 酮;epoxymexrenone )的一個有利之新方法。 本發明之方法中的一個關鍵步驟是化學式Η之新類固醇中 間產物在一路易士酸觸媒存在下與一親核劑發生反應,
其中1和1係單獨自Η,C(0)0R^C0R^出以及1或尺2中 至少有一個是c(o)or2或cor2 ; Ζι,Z2,R2和Q同化學式I所示; 4親核劑係選自C 1 ·4-三坑基碎燒基氰化物、C 1 ·4-三燒基碎燒 基烯醇醚、C〗·4-三烷基矽烷基氧烯酮硫縮醛(即 RCH-C(OSiR3) SRC]·6燒基)、晞丙基三-C1·4-燒基碎燒、埽丙 基三-Cw烷基錫烷、2-Cw烷基呋喃和2-Cw烷基吡咯。 在化學式II之化合物中殘留一烯丙基醇類衍生物之結構 元素於C-5,-C6,-C7-OR3。由此「烯丙化」反應所獲得之 84103-950628.doc -7- 1280133 新合成圖示將於「具體實例之說明」中詳細說明。 實施方式 定義 在此詳細說明中,將使用下列定義。 「烷基」這個名詞,就其本身或是當成另一取代基之部 分,意指(除非另有說明)一直鏈或帶有支鏈或是環烴自由 基,或三者之結合。飽和烴自由基之實例包括(但不限於)例 如甲基、乙基、正-丙基、異丙基、正-丁基、第三丁基、異 丁基、第二丁基、環己基、(環己基)乙基、環丙基甲基、例 如正-戊基、正己基、正庚基、正辛基和其他類似之同系物 和異構物。 •「芳基」(Ar)這個名詞,可單獨使用或和其他名詞結合 使用(例如芳氧基、芳硫氧基、芳烷基),係指(除非另有說 明)一個單環或多環(最多三個環)之芳取代基,其係融合在 一起或以共價鍵結。 「親核劑」這個名詞意指如Morrison,R. T·,et. al·, Organic Chemistry,6 edition,Prentice Hall pub·,1992,p. 172.中說明之傾向於攻擊碳核之富電子試劑。 「路易氏酸」這個名詞意指如McQuarrie, D· A·,et. al·, General Chemistry, third edition, W. H. Freeman and Company pub·,1991,p. 665.中定義之電子對接受者。 驚訝的是,發明人已經發覌化學式II之C-7-羥基-C-5A6-烯 類固醇之羧基衍生物將和多種親核劑發生烯丙化反應以產 生如表一所示之化學式I之對應C-7取代類固醇衍生物。適 84103-950628.doc 1280133 用之親核劑包括(但不限於)在一路易士酸觸媒存在下之ci-4-三烷基矽烷基氰化物、C1-4-三烷基矽烷基烯醇醚、C1-4-三烷基矽烷基氧烯酮硫縮醛(RCH^qOSiRdSRCu烷基)、烯 丙基三-C卜4-烷基矽烷、烯丙基三-C1-4-烷基錫烷、2-C1-4-烷基呋喃和2-C1-4-烷基吡咯。適用之路易士酸包括(但不限 於)過渡元素三氟甲磺酸鹽(triflates) (0Tf=0S02CF3)例如 Sc(OTf)3、Ce(OTf)3、Fe(C104)2、Cu(C104)2,和 Yb(OTf)3,以 及鉬(II)錯合物如 Mo(CO)5(OTf)2和[Mo(CO)4Br2]2。 類固醇受質 親核劑 觸媒 溶劑/溫度 產物 產量 % OAc :.. AcO^^^OAc 1 TMSCN Sc(OTf)3 乙腈/RT • OAc AccA^^CN 18 40 Me02CO*^^^〇C〇2Me Η 二甲基呋喃 Sc(OTf)3 二氯甲烷 0-15〇C Μβ〇人 έ a iy 74 ,υ Me02C0-s>vJj( * Me02C0 人y"^〇C02Me III 二曱基呋喃 Sc(OTf)3 乙腈/室溫 · Ρ Me〇2ca.^vUi Me02C0 人八^ . 20 96 x#' AcO^^^^OAc IV 二甲基呋喃 Sc(OTf)3 二氯甲烷/室 溫 \ · … ,21 63 二曱基呋喃 Sc(OTf)3 乙腈/室溫 87 二甲基呋喃 Ce(OTf)3 乙腈/14〇C 77 二曱基呋喃 Yb(OTf)3 乙腈/室溫 96 Acc/^^^OAc V Sc(0Tf)3 乙腈/室溫 人jC^ 22 83 TMSCN=三甲基石夕燒基氰化物 表1 84103-950628.doc -9- 1280133 然而,在相似情況下,啕哚和苔黑酚之產量小於i〇°/。且生成 錯化物混合物。乙烯三甲基矽烷和三甲基矽烷基乙醯烯不 會反應。 圖不概要 如上述,化學式I之化合物可用於作為依普利酮之合成的 起始物。反應圖I和II提供一利用本發明方法製造之化學式I 之化合物製備依普利酮之反應流程圖例。 〇
〇 〇
依普利酮
圖示I 84103-950628.doc -10- 1280133
Il-B Il-F 11-H 11·0
II-J
圖示II 作為圖示I-II之起始物1(圖示1)(3 yS,7 /9 -11 α-三經-5-雄固婦- 84103-950628.doc -11 - 1280133 17-酮)之製備可由兩種方式獲得。一種方法是使5-雄固婦-3/3-醇-17-酉同首先接觸一浸有ATCC 20571(同
IFO 6469)的培養基以產生一5-雄 固晞-3石,7沒-二醇-17-酮(見實例1〇),之後讓5_雄固晞-3 /9,7 /5 - 一醇-17-酮與一個浸有 oc/zracews ATCC 18500之培養基接觸以產生5-雄固烯-3冷,7β,11 α -三醇-17 -酮 1(圖示I)。或者,可將5-雄固錦Γ-3泠-醇-17-酮與一浸有 ^ cmm/m ATCC 6647之培養基接觸以產生5_雄固烯 召,7β,11 α -三醇-17-酮1(圖示I)。 步騾Ι-A和ΙΙΒ 羥基中間產物1和11(圖示II)在一個三級有機鹼存在下藉由 此技藝中冰知之方法利用一酸化劑使其發生酸化作用以產 生2和12。酸化劑包括低醇酐、低醇基氯化物、低烷基羰基 氯化物、低烷基碳酸酐和其類似物。適合的三級有機驗包 括吡啶、4-二甲基胺基吡啶、三乙基胺、二異戊基乙基胺 和其類似物。或者,混合碳酸鹽(R〇_C〇_〇_)之製備可利用 已公開的方法(Harada,T·,et. aL,j. carbohydrate Chem (1995),14,165)經修飾而在一三級有機鹼存在下藉由其與一 坑氧基羰基氧苯三峻的反應而達成。
步驟I-B和II-E 經三醯化之化合物2(圖示I)和14(圖示π)在一路易士酸存在 下,通常在一惰性溶劑例如乙腈或二氯甲烷 - 覜核 劑所發生之反應,分別產生3(圖示υ*15(圖示π)。適用之 親核劑包括(但不限於)三烷基矽烷基氰化物、夂矽燒取代= B4103-950628.doc -12- 1280133 屬烴、烯醇醋酸酯、矽燒基烯醇醚、烯丙基錫燒、N-燒基 吡咯、N,N-二烷基苯胺、矽烷基烯醇硫醚、矽烷基烯醇醚 和富電子之雜芳族例如2-烷基取代呋喃。適用之路易士酸 包括(但不限於)過渡元素三氟甲磺酸鹽(〇Tf = 〇S〇2CF3),例 如 Sc(0Tf)3、Ce(0Tf)3 和 Yb(〇Tf)3,以及鉬(Π)錯合物如 Mo(CO)5(〇Tf)2和[Mo(CO)4Br2]2。
步驟Ι-C和II-F 3(圖示I)和5(圖示II)之醯基經水解反應以產生4(圖示I)或 16(圖示II)可利用甲醇當成溶劑,並視情況加入一共溶劑, 使用一鹼土族氫氧化物、碳酸氫鹽或碳酸鹽如氫氧化鈉、 碳酸鉀、碳酸氫鈉、氫氧化铯、碳酸氫鋰和其類似物以完 成反應。
步驟Ι-D和II-A 如文獻(見實例:Schwede,W·,et.al·,Steroids,63 166(1998); Corey,E. J. et.al·,J. Amer.Chem.Soc.(1999),121,710-714; Schwede,W. et.al·,Steroids(1998),63(3),166-177; Ali,H. et.al·,J. Med· Chem.(1993),36(21),3061; Turuta,A· M. et.al·, Mendeleev Commun. (1992), 47-8; Kumar, V. et.al·,
Tetrahedron (1991), 47(28), 5099; Page, P. C·,
Tetrahedron(1991), 47, 2871-8; Curts, S. W. et. al·,
Steroids(1991),56,8; Kataoka,H. et· al·,Chem. Lett. (1990), 1705-8; Christiansen, R. G. et. al·,J. Med. Chem. (1990), 33(8),2094-100)所述步騾,17-酮氧中間產物4(圖示I)和1(圖 示I)可與乙炔反應以提供對應的加成化合物5(圖示I)和11(圖 84103-950628.doc -13· 1280133 示II)。視情況,在步騾II-A中之三羥基化合物1可在添加乙 炔前未經分離下進行三甲基矽烷化反應。矽烷化反應可利 用六曱基二矽氨烷和一微酸觸媒例如氯化三甲基矽烷或糖 精反應而達成。隨乙炔加入後,於進行微礦物酸、醋酸、 磷酸、氣化四-烷基銨和其類似物反應期間將三甲基矽烷基 移除。
步驟E
乳酸-/3 -莕酯中間產物6(圖示I)和13(圖示II)之形成可如文獻 (Wuts5 P. G. M.? et. al.? J. Org. Chem. 1989? 545 5 180; Botteghi,C·,et· al·,Tetrahedron,2001,57,1631)中說明的方 法由5和12與一氧化碳和氫在一達催化量的錢觸媒和一錢對 應配位子的存在下進行氫化甲醯反應而達成。此反應可在 每平方吋14_500磅(psi)的壓力下發生,最佳壓力範圍是每平 方吋100-200磅(psi)。氫和一氧化碳的比例從1/5至5/1皆可, 最佳比例為1/1。適合的铑觸媒包括醋酸铑、氯化鍺和二羰 基乙醯丙酮鍺II。適合的配位子包括三芳膦、三烷基亞磷酸 酯、雙配位基膦例如xantphos、二齒亞磷酸鹽和其類似物。 步驟I-Fa和II-D 6(圖示I)形成6a以及16(圖示II)形成7(圖示II)之氧化反應可 由多種標準氧化劑達成。適合的氧化劑實例包括:碘琥珀 酿亞胺 / 四 丁基铵蛾化物(Kraus,George A· Bioorganic & Medicinal Chemistry Letters (2000),10(9),895-897; Barrett, A. G. M·,et· al·,J. Org. Chem. (1989),54(14),3321);瓊斯 試劑(絡酸在丙酮中)(Panda,J·,et· al·,Tetrahedron Letters 84103-950628.doc -14- 1280133 (1999),40,6693; Tomioka,K·,et· al·,J· Org· Chem· (1988), 53(17),4094);碳酸銀(Chow,T· J·,et. al·,J· Chem. Soc·, Perkin Transactions 1,(1999),1847 );氯鉻酸 p比錠 (Pyridinium chlorochromate)(Uchiyama5 M·, et. al·, Tetrahedron Letters (2000),41(51),10013; Vanderiei,J· M. de L.,Synthetic Communications (1998),28(16),3047; Kassou, M·,et. al_,Journal of Organic Chemistry (1997),62,3696; Rehnberg,N·,et. al·,J. Org. Chem. (1990),55(14),4340-9; Ru04/四燒基铵鹽/三級胺N-氧化物,Jeewoo,K·,et· al·,Chem. Lett. (1995),(4),299;二絡酸 p比錠(pyridinium dichromate), Paquette,L. A·,et· al·,J. Am. Chem. Soc. (1995),117(4), 1455-6);次氯酸納 / 三級胺 N-氧化物(Waldemar,A·,et. al·, Chem· Rev·,(2001),101,3499);鋁烷氧化物/丙酮(〇oi5 T·, et· al·,Synthesis (2002),279); Djerassi,C. et· al·,Org. React. (1951),6, 207);三丙酮氧四碘茚烷(Martin,J. C.,et· al·,J· Amer. Chem. Soc”(1991),113, 7277)。 步騾Fb 在此些發生在步騾Fa之未共軛5-6雙鍵的氧化反應範例中, 在6a(圖示I)將雙键由C5-6位置移入C4_5位置之過程可在一惰 性有機溶劑或一水性混合溶劑中於溫度〇°C - 80°C利用6a(圖 示I)與一有機或無機酸進行接觸而完成。適合之有機酸包括 (但不限於)甲苯磺酸、甲烷磺酸、苯磺酸、三氟醋酸、草 酸、三氣醋酸和其類似物。適合之無機酸包括(但不限於)氫 氣酸、氫溴酸、磷酸、過氯酸和其類似物。或者,觸媒可 84103-950628.doc • 15 - 1280133
為一三級有機鹼如三乙基胺、二氮雜雙環十一烷(DBU)和類 似物或一無機驗如氫氧化鋼、氫氧化钾、氫氧化#5和其類 似物。雙鍵移入反應已說明於Bakshi,et. al·,U.S· Patent No. 5,237,064; Pollack, et· al·,J· Amer· Chem. Soc” 1987,109, 5048; Tsubuki, et. al.? J. Org. Chem.5 1992,57,2930; Zeng, et. al·,J. Amer. Chem. Soc.,1991,113,3838 o 步驟I-H和IM,J 11-羥基中間產物7(圖示I)和18(圖示II)之脫水反應可利用已 說明於U· S. Patent 4,559,332之五氯化磷來完成。或者,11-羥基中間產物可轉變成一磺酸酯,例如一甲烷磺酸酯或一 對·甲苯磺酸酯,接著如在WO97/21720和W098/25948所說明 之以一個鹼作用在脫水反應中來處理而完成。
步驟I-H和II-H 在7(圖示I)中之呋喃環降解成8(圖示II)之甲基酯可由實例中 所說明之臭氧分解、氧化作用和酯化作用而完成。
步驟I-J和II-K 此已知中間產物9(圖示I)至1〇(圖示π)(依普利酮)的轉化反應 在美國專利號碼4,559,332和5,981,744中已說明。 實例 起始物1之製備,方法1 步驟1 : 5-雄固烯-3 /5 -醇-17-酮行生物轉化成5-雄固烯-3冷,7 /3 -二醇-17-酮 84103-950628.doc •16- 1280133
5-雄固烯·3万-醇-17-酮之生物轉化成5-雄固晞-3/5,7;3 -二 醇-17-酮是利用一浸有ATCC 20571(同 IFO 6469)的培養基在一 10公升之 發酵槽中進行。 (A) —級接種階段 1)0/6^以尽〇5^即〜(2(八丁〇€2〇571)之冷滚植物性細胞經解 凍,轉換到蕃薯-右旋糖-瓊脂板(PDA),並在28t培養72小 時。單一菌絲塞(直徑6-7 mm)可用以接種至一含100 mL — 級接種培養基之矽化(500 mL)脫色振盪燒瓶内。一級接種 培養基的組成份(每公升逆滲透水)為··右旋糖50 g、黃豆 粉 35 g、cerelose 5 g、氯化姑六水合物(cobalt chloride hexahydrate) 2 mg、聚矽氧消泡劑(SAG 471) 0.5 mL,以氫 氣化納(2 N)將預滅菌之pH值調整至7.0-7.2。將Diplodia gossypina ATCC 2〇571接種至培養基並利用一環境控制培養 箱震盈器以280 r.p.m. ( 1n orbital stroke )之速度震盡在28 °C 下培養48小時。 (B)二級接種階段 1 〇升二級接種發酵作用可利用1.2 mL植物性一級接種培 養基(0.012 % [v/v]接種率)來接種。二級接種培養基含有(每 公升逆滲透水):cerel〇se 60 g、黃豆粉25 g、大豆油30 84103-950628.doc -17· 1280133 mL、硫酸鍰七水合物1 g、二氫磷酸钾0.74 g、聚氧乙基二 烯花楸丹單油酸2 mL、聚矽氧消泡劑(SAG 471) 0.5 mL,利 用濃縮之硫酸將預滅菌pH值調整至3.95-4.00。内含二級種 子培養基之發酵器可利用套層和喷射兩種蒸氣法於121°C滅 菌20分鐘。滅菌期間之攪拌速率是200 r.p.m.。後滅菌作用 進行時,利用無菌硫酸(5%)將培養基pH值調整至4.0。利用 下列初參數於28°C 培養Diplodia gossypina ATCC 20571 :以 100 r.p.m.攪拌、背壓=5 psig、氣流=2.5 SLM (0.25 VVM)、低DO設定點30%、不需控制pH值。當DO值首次降 至30%時,氣流將增加至5 SLM (0.5 VVM)。當培養基再度 達到低DO值時,可利用攪拌控制維持30%之DO值。於大約 經過60小時之後接種過程,當OUR大約介於10和15 mM/L/h 之間時,即可得二級接種培養基。 (C )類固醇生物轉化作用 10升類固醇發酵作用可利用500 mL植物性二級接種培養 基(5%[v/v]接種率)來接種。類固醇生物轉化培養基和二級 接種培養基相同,滅菌條件和pH值調整係如同說明過之二 級接種培養基。乃ATCC 20571於28°C利用 基本上與那些在二級接種培養基中使用之初參數相同之條 件進行培養,例外的是低DO設定點將從30%增高至50%。 當DO值首次降至50%時,氣流將從2.5 SLM (0.25 VVM)增加 至5 SLM (0.5 VVM)。當培養基再度達到低DO值時,可利用 攪拌控制維持50%之DO值。開始於24小時後接種作用中, 將經微米化且攪入一極小體積之0.2%聚氧乙烯花楸丹單油 84103-950628.doc -18- 1280133 酸之5-雄固晞_3 以每_小時之時間間隔加入到發 酵作用中直至加入總量達400 g為止。在大約3天之後接種培 養中’將額外之100 g cerelose加入10 L發酵作用中。 生物轉化培養基應利用TLC每日檢定其5_雄固晞_3々,7冷_ 二醇_17-酮。一毫升之全啤酒可用10 mL甲醇萃取。細胞可 利用離法(3,〇〇〇 X g離心1 〇分鐘)由水性一甲醇混合物 中分離出,且有數微升可應用在TLC板上。TLC板由環己 k ·醋fe乙酯:甲醇(90:60:15)發展出來且此產物可藉由將 50%硫酸噴霧灑在TLC板上接著在烤箱中烤成焦黑狀看出。 將產物和人造標準產物比較後發現,此產物經噴麗5〇%硫酸 後會轉為藍色。5-雄固缔_3万-醇-17-酮經生物轉化完全轉化 成5-雄固烯-3 /3,7β-二醇-17-酮約需4天之後接種作用。 (D)分離方法 將培養中之全啤酒固體經過離心並利用離心方法恢復其 豐冒固體。利用10 L二氯甲烷萃取豐富固體部分且利用離 心方法恢復其豐富萃取物溫萃取物。將萃取物經磨光並利 用蒸館將其濃縮至大約1升且將結晶漿狀物冷卻至_ 1 〇 〇C, 結晶可經由過濾、復原、以二氯曱燒清洗使之脫色並經乾燥 而產生227公克之5-雄固婦_3,,7β-二醇-17-酮之純化結晶 物0 步驟2 : 5-雄固烯-3万,17 /9 -醇-17-酮之生物轉化形成5-雄固 晞-3点,7β,11 α -三醇-17 -酮 84103-950628.doc -19- 1280133
5-雄固晞-3 /5,17 /5 -醇-17-酮之生物轉化成5-雄固烯-3 召,7β,11 α -二醇-17-酮可利用一含有 oc/zracews ATCC 185〇0(同NRRL 405)之培養基在一個10公升發酵槽中 進行。 (A) —級接種階段 oc/zracew ATCC 18500之一級接種培養基可如 貫例12中所說明用以製備£)0/6^0容6^外^0八丁(^2〇571之 方法來製備。 (B )二級接種階段 10升二級種子發酵作用可利用mL植物性一級種子培 養基(0·012 %[v/v]接種率)來接種。二級種子培養基含有(每 公升逆滲透水):cerel〇se 4〇 g、黃豆粉25 g、黃豆油3〇 & §义鑊/、水B物1 g、二氫磷酸鉀〇·74 g、壬基盼氧聚 乙氧基乙醇0.25 mL、聚矽氧消泡劑(SAG 471) 〇·5 mL,利 用/辰%之硫酸將預滅菌1)11值調整至3 95_4 〇〇。内含二級種 子培養基之發酵器可利用套層和噴射兩種蒸氣法於i2rc滅 菌μ分鐘。滅菌期間之攪拌速率是謂rp m•,後滅菌作用 進仃時’利用無菌硫酸(5%)將培養基調整至4〇。利用
下列初始參數於28 °C下掉盖j ·77 7 ^ 1 ^ ^ Aspergillus ochraceus ATCC 18500 ·•以 loo r.p m•攪拌 ·片 祝开 目壓=5 psig、氣流=2.5 SLM S4103-950628.doc '20- 1280133 (0.25 VVM)、低DO設定點50%、不需控制pH值。當DO值首 次降至50%時,氣流將增加至5 SLM (0.5 VVM)。當培養基 再度達到低DO值時,可利用攪拌控制維持50%之DO值。經 50-54小時之後接種過程,當OUR大約介於20和26 mM/L/h之 間時即可得二級接種培養基。 (C)類固醇生物轉化作用 10升類固醇發酵作用可利用500 mL植物性二級接種培養 基(5%[v/v]接種率)來接種。類固醇生物轉化培養基基本上 和二級接種培養基相同,例外的是壬基酚氧聚乙氧基乙醇 將從0.25 mL/L增至2 mL/L,且以濃縮硫酸將預滅菌過程之 pH值調整至2.95-3.00。滅菌條件和說明過之二級接種培養 基相同。後滅菌過程中,培養基之pH值利用無菌硫酸(5%) 調整至3.0。oc/zraeew ATCC 18500 於 28°C利用基 本上與那些在二級接種培養基中使用之初參數相同之條件 進行培養,例外的是攪拌最初是設定在200 r.p.m·。在大約 1 8小時之後接種作用中,將2 0 0 g經微米化之5 -雄固晞-3/5,7/3-二醇-17·酮,並且攪入一極小體積之0.2%壬基酚氧 聚乙氧基乙醇加入到10 L發酵作用中。 生物轉化培養基應利用TLC每日檢定其5-雄固烯-3/5,7y3,llα-三醇-17-酮,如實例10所說明。5-雄固烯-3yS,7y5-二醇-17-酮經生物轉化完全轉化成5-雄固晞-3万,7β,11 α -三醇-17-酮 約需4天之後接種作用。 (D)分離方法 將培養中之全啤酒固體經過離心。將液體丟棄,利用10 84103-950628.doc -21 - 1280133 L 80%丙酮20%水於45。〇至5〇t萃取豐富固體部分且將溫萃 取物利用過濾、法使之澄清。豐富滤液經蒸餾法濃縮以除去 會產生粗結晶水性漿液之丙酮。結晶漿液經過攄後將母液 丟棄。水濕性結晶可用600 ml:氯甲烷研製以除去不純物, 並將之溶解在700 ml甲醇中(藉由加熱至55。〇 ,並在之後 利用5 g Darco G-60碳脫色。經過濾除去碳之後,濾物可經 濃縮結晶出此產物。此甲醇可進一步利用加入3〇〇 mL正-丁 基醋酸加以除去並濃縮成一厚漿狀結晶。結晶物經過濾 後,以醋酸正丁酯清洗,並予以乾燥產生158 §之5-雄固晞· 3 /5,7β,11 α-三醇-17-酮之純結晶物。 1之製備,方法2·· 5-雄固婦-3;3_醇_17_酮之生物轉化形成弘 雄固晞-3 yS,7β,11α-三醇-17·酮
5-雄固烯-3/9 -醇-17-酮之生物轉化成5-雄固烯-3/5,7β,11α-三醇-17-酮可利用一含有coerw/M ATCC 6647之培養 基在一個10公升發酵槽中進行。 (A) —級接種階段 dhzWa coerw/ea ATCC 6647之一級接種培養基可如實例12中 所說明之用以製備Dz>/o心αATCC 20571之方法來 製備。 84103-950628.doc -22- 1280133 (B )二級接種階段 10升二級接種發酵作用可利用12 mL植物性一級種子培 養基(〇.〇12 %[v/v]接種率)來接種。二級接種培養基含有 沒公升逆滲透水):右旋糖5〇 g、黃豆粉35 g、⑽_ 5 §、 氯化鈷六水合物(cobalt chl〇ride hexahydrate) 2 mg、聚矽氧 消U(SAG 471) 0.5 mL,以氫氧化鋼(2 N)將預滅菌之pH 值調整至4.95-5.00。内含二級種子培養基之發酵器可利用 套層和噴射兩種蒸氣法於⑵。C滅菌20分鐘。滅菌期間之攪 拌速率是200 r.p.m.,|減菌作用進行時,利用無菌硫酸 (5%)將培養基pH值調整至5〇。利用下列初始參數於以艺下 培養槪‘⑽‘ ATCC 6647 :以1〇〇 rp爪揽摔、背壓 =5 pS1g、氣流=2.5 SLM (〇 25 VVM)、低〇〇設定點腦、 不需控制pH值。當D0值首次降至3〇%時,氣流將增加至$ Μ (0.5 VVM)。當培養基再度達到低D〇值時,可利用攪 拌控制維持30%之D0值。經76小時之後接種過程,當〇ur 大約介於4和7 mM/L/h之間時即可得二級接種培養基。 J c)類固醇生物轉化作用 1〇升類固醇發酵作用可利用500 mL植物性二級接種培養 基(5%[V/V]接種率)來接種。類固醇生物轉化作用培養基含 有(每公升逆滲透水):右旋糖50 g、黃豆粉35 g、 ㈣ose 20 g、聚魏消泡劑(SAG 471) 〇 5虹,以濃縮硫 酸將預滅菌之pH值調整至2·95·3·〇〇。滅菌條件和pH值調整 和說明過之二級接種培養基相同。後滅菌作用中,培養基 之PH值可利用無菌硫酸(5%)調整至3.G。施加⑽心。 84103-950628.doc -23- 1280133 ATCC 6647於28°C利用基本上與那些在二級接種培養基中使 用之初參數相同之條件進行培養。於17小時後接種作用 中,將200 g經微米化之5-雄固烯-3/3-醇-17-酮,攪入一極 小體積之0.2%壬基齡氧聚乙氧基乙醇加入到1〇 l發酵作用 中0 生物轉化培養基應利用TLC每日檢定其5-雄固烯-3 /3,7 f, 11α-三醇-17-酮,如實例1所說明。5-雄固婦-3石-醇-π-酮 經生物轉化完全轉化成5-雄固烯-3点,7β,1 Ια -三醇-171同約 需經6-7天之後接種作用。/ (D)分離方法 全啤酒固體可經過離心而復原。將液體丟棄,利用1〇 L 85。/〇丙酮15%水於45°C至50°C萃取豐富固體部分且將溫萃取 物利用過濾法使之澄清。豐富濾液經蒸餾法濃縮以除去會 產生粗結晶水性漿液之丙酮。結晶漿液經過濾後將母液丟 棄。水濕性結晶可用600 ml二氯甲烷研製以除去不純物,並 將之溶解在700 ml甲醇中(藉由加熱至55°C ),並在之後利 用5 g Darco G-60碳脫色。經過濾除去碳之後,濾物可經濃 縮結晶出此產物。此甲醇可進一步利用加入3〇〇 mL醋酸正 丁酯加以除去並濃縮成一厚漿狀結晶。結晶物經過遽後, 以醋酸正丁酯清洗,並予以乾燥產生75·5 ^之5_雄固晞_3 )5,7β,11α-三醇-17-酮之粗結晶物。 此粗結晶物可用600 ml二氯甲燒研製以除去不純物,並將 之溶解在700 ml甲醇中(藉由加熱至55°C ),並在之後利用 5 g Darco G-60碳脫色。經過濾除去碳之後,濾物可經濃縮 84103-950628.doc -24- 1280133 結晶出此產物。此甲醇可進一步利用加入300 mL醋酸正丁 酯加以除去並濃縮成一厚漿狀結晶。結晶物經過濾後,以 醋酸正丁酯清洗,並予以乾燥產生42.1 g之5·雄固烯-3 yS, 7β,11α-三醇-17-酮之純結晶物。 實例1 :三碳酸2之形成。 利用一 3 Ν 250 ml RBF將三元醇1 (圖示j) (1〇 〇〇 g,31 mmol)溶解在吡啶(100 ml)中,在此溶液中加入三乙基胺(31 ml, 218 mmol)、碳甲氧基苯三唑(24.2 g,125 mmol)和 4-N,N-二甲基胺基吡啶(1.2 g5 9 ·4 mmol)。將此漿狀物攪拌2小時使 所有物質全部溶解,加入額外的碳甲氧基苯三唑(12 g,62 mmol)和三乙基胺(10 ml,73 mmol)。一旦固體溶解,反應就 已%成。緩慢加入水(300 ml)並在冰浴中將此混合物冷卻。 將沉澱物過濾並以10% HCl(2x35 ml)和己燒(3x50 ml)清洗並 在真空烤箱中乾燥24小時以獲得標題化合物2 (圖示j )。 13C NMR(CDC13) 6 217.78,155.60,155.23,154.88,144.48, 122.35,78.58,76.81,75.39,55.29,54.93,51·09,49·47,47·79, 38.48, 37.89, 36.19, 36.08, 27.96, 23.58, 19.G7, 14.4G。 實例2 :吱喃3之形成。(圖示I ) 將此反應7 mL乙腈中之三碳酸酯2 (1·〇 g,2·02 mmol)溶液利 用一 2-甲基呋喃(〇·2 mL, 2.22 mmol)和 0.298 g之 Sc(OTf>3處 理一小時。利用薄層色層分析法TLC (30% EtOAc/Hex)顯示 此反應已完成。以矽膠利用25% EtOAc/Hex進行色層分析法 可產生 〇·92 g(96%產量)之呋喃 3。13C NMR(CDC13) 5 217.88, 171.08,155.34,154.93,152.38,151.49,140.72,123.98, 84103-950628.doc -25- 1280133 110.56,1G6.45,77.5G,75.89,6G.51,54.98,54.71,47.45, 46·57, 38.73, 37.66, 36.21,35·91,27.96, 22.22,19.14,13.98, 13·77 〇 實例3 :二元醇4之形成。(圖示工) 將二碳酸酯3 (1.0 §)於10 mL Me〇H之溶液經5〇〇 mg K2C〇3處 理並加溫至40°C。將此混合物攪拌至TLC顯示此反應已完 成。元成時將此漿狀物倒入水中且產物可以Et〇Ac分離。有 機濃縮物將產生二元醇4之黏性油脂。iH NMR(CDCl3)55.7 (s,H),5.45(d,J=5.7 Hz,1 H),3.45(m,1 H),3.29(t,J=5.1 Hz,1 H),2.09(s,3 H),l.l(s,3 H),〇.75(s,3 H)· 實例4 :炔屬烴5之形成。(圖示I) 將一 2·8 g (25·0 mmol) t-Bu〇K 之 50 mL· THF 之溶液在-1(TC 下 利用乙決噴霧30分鐘。之後在持續進行乙炔噴霧緩時慢慢 加入10 mL THF中之酮類π溶液。在〇它攪拌此混合物一 小時並在之後加入含2.0 mL醋酸之10 mL水。在將混合物倒 入水中之後以EtOAc萃取液分離出此產物。利用甲苯共沸液 除去醋酸。此NMR光譜證明有少量醋酸和甲苯的存在。產 量 2.25 g。13C NMR(CDC13)(5 153.77, 151.21,142.66, 122.83, 110.12, 106.1,87.3, 79.42, 74.03, 72.29, 69.48, 50.61,47.49, 45.70, 43.64, 42.87, 39.38, 39.06, 38.295 37.68, 31.84 23 7 21.26, 19.27, 14.19, 13.9 〇 實例5 :乳酸-yS-莕酯6之形成。(圖示I) 將一 1.55 g炔屬烴 5 (圖示 I ) 、27 mg Rh2(〇Ac)2和 92 mg PhP於20 mL EtOAc中之溶液利用CO加壓至100 psi並用仏加 84103-950628.doc -26- 1280133 壓至100 psi並加熱隔夜至8(rc。將混合物濃縮並以矽膠利 用90% EtOAc/Hex進行色層分析可產生2部分。部分ι利用 NMR顯示可恢復成起始物。部分2是希望得到之乳酸_点_苒 酯。CMR顯示乳酸-召-莕酯混合物在94 8和94 5 ppm有訊號 顯示。 實例6 : 5, 6-烯酮6a之形成。(圖示I ) 將一 2.0 g乳酸-冷-莕酯、50 mg溴化鉀、12 mg TEMPO、800 mg NaHC〇3之混合物於20 mL之CH2CI2和5 mL水中冷卻至5
°C,之後緩慢以8 mL之1.1 M NaOCl處理此混合物並保持溫 度在6°C以下。經此加成反應之後攪拌此混合物30分鐘之後 並利用CH^Cl2將產物分離出以產生6a (圖示I) 。13c NMR (CDC13) δ 209.82,176.37,153.19,151.78,143.34,128.15, 121.41,110.62,106.53,94.35,72·0,55.39,50.44,47.99, 44.41,42.26,39.03,38.63,37.1,35.67,31.9,29.19,23.39, 18.33, 15.69, 14·07 〇 實例7:利用酸形成4,5_晞酮7(圖示I)。 將一 5,6-烯酮6a (圖示I ) (500 mg)和草酸(200 mg)之混合物 在乙醇(10 ml)中於40°C加熱三小時。在減壓下除去乙醇並 將殘留物溶解在醋酸乙酯(50 ml)中,將此有機溶液用水 (2x50 ml)清洗過,以硫酸鈉乾燥並加以濃縮。此殘留物可 利用管柱色層分析法以矽膠加以純化而得到4,5-烯酮7 (圖 示I) 0 實例8 :利用鹼形成4,5_烯酮7。 將一 5,6-缔酮6a (500 mg)和DBU(200 mg)之混合物於四氫吱 84103-950628.doc -27- 1280133 喃(5 ml)以回流方式加熱三小時,之後冷卻並用氯化銨溶液 稀釋以及用醋酸乙酯萃取。此萃取物用硫酸鈉乾燥並加以 濃縮。此殘留物可利用管柱色層分析法以矽膠加以純化而 得到4,5-烯酮7。 實例9 :二晞酮9之形成(圖示I )。 將1.2 g醇類7之溶液溶解在10 mL之THF中並冷卻至_33°c, 之後將PC15(950 mg)全部一次加入。將溶液在_33°C下揽拌 三小時之後並加水淬火。利用EtOAc將產物分離出而產生二 烯9 (圖示I )。利用矽膠色層分析法以Et〇Ac/Hex加以純 化。 實例10 ··由呋喃取代物形成甲基酯。
方法A
將一吱喃衍生物8 (圖示I) (ι·〇 g,2.280 mmol)在100 ml二氣 甲烷之溶液冷卻至-79°C,將一臭氧/氧(〇3/〇2)氣流通過此溶 液10分鐘,之後將此混合物加溫之室溫,並濃縮成固體殘 留物,將此放入50 ml 1/1甲醇/二氯甲烷中,以1〇⑹吡 呢處理’並在室溫下攪拌18小時。之後將此溶液冷卻至-j 8 °C。將一臭氧/氧(〇3/〇2)氣流通過此混合物4小時,之後用 84103-950628.doc -28- 1280133 100 mi醋酸乙酿稀釋此混合物並用7〇ml碳酸氫鈉水溶液萃 取之。水相部分以氫氯酸水溶液進行酸化至ρΗ 〇·5,之後用 二氯甲燒萃取並濃縮成一泡沫(重:25〇 mg)。將此泡沫溶解 在甲苯/甲醇中,在室溫下以三甲基料基二偶氮甲燒(〇5 ml之2.0 Μ溶液在己烷中,lo mm〇les)處理’之後將此溶液 濃縮得到一如同油脂之酯9。
方法B 步驟 1) 5a,17yS-二經基氧娠-9(11)-婦-3-酮、7α,21-二羧 酸、雙-7 -内酯8a (圖示I)。 0
將一 17/3_羥基-7〇:-(5,-甲基-2,-呋喃)_娠基_4,9(11)-二烯_ 3-酮-21-羧酸、7 -内酯(1〇〇 g,0 23778 m〇les)和醋酸鉀 (50·0 g,0.5094 moles,2.14當量)在丙酮(5〇〇 ml)和水(15〇 m!) 中之落液冷卻至-10°C並在水(100 ml)中以一 dibromantin之漿 狀物(34 g,0.1189 moles,0.50莫耳當量)處理直到一氧化還原 電位發生升高情形為止。於此,可利用液體層析顯示其完 全轉化成烯二酮(III-順式)。含有缔二酮(ΙΠ-順式)之反應混 合物接著利用異丁基乙雄基ml,0768 g,7.668 mmoles,0.032當量)產生淬火,濃縮成一厚漿狀物,利用二 84103-950628.doc •29- 1280133 氯甲烷(2〇0 ml)稀釋之,並以2〇。〇濃縮之氫氯酸(5〇 〇 ml, 0.50 moles,2.10當量)處理。此混合物於20-25 °C揽掉2小 時,此時可利用液體層析法方析顯示完全轉化成婦二酬 (III-反式)。分離出含有烯二酮(III-反式)之有機相,以二氯 甲烷(80 ml)和甲醇(300 ml)稀釋,並冷卻至-48°c。將一臭 氧/乳(〇3/〇2)氣流通過此混合物產生氣泡直到液體層析顯 示錦二酮(III-反式)冗全消失為止,接著利用硫化二甲基 (30·0 ml5 25.38 g,0.4085 moles, 1.72當量)使此混合物淬火, 於-20 C揽拌16小時,濃縮至體積約300 ml,以甲醇(35〇 mi) 稀釋,濃縮至體積約300 m卜利用異戊醇(40 ml)和甲醇(8〇 ml)將之稀釋,之後利用一溫熱(55_6〇。〇之碳酸氫_(12〇 g, 1.1986 moles,5·04當量)溶液在水中(240 ml)加以處理。將此 漿狀物冷卻至5-10°C,之後加入過氧化氫(50%, 66.0 g,含 有33.0 g(0_9703 moles,4.08當量)過氧化氫)超過三小時。攪 拌此混合物四小時並以硫化二甲基(40 ml,33.84 g,0.5447 moles,2.29當量)加以淬火。經過20_25^攪拌23小時之後, 利用二氯甲烷(100 ml)和水(80 ml)稀釋此混合物,並用濃縮 之氫氯酸進行酸化至pH值=3.0。將此雙相混合物加熱至36 °C,之後兩相分離並將水相以二氣甲烷(1〇〇 ml)萃取。將有 機相結合,以水(75 ml)清洗,且將水相以二氯甲烷(25 ml) 回復萃取,將有機相結合,濃縮至體積15〇 ml,之後以苯磺 酉艾(1.0 g 之 90%純物質’含有 〇9〇 g(5.690 mmole,0.0239 當 量)苯磺酸)及丙酮(50 ml)處理。之後將此混合物於大氣中 濃縮至體積160 ml,之後以丙酮(25〇 mi)稀釋,濃縮至體積 84103-950628.doc -30- 1280133 200 m卜冷部至12 C,並加以過濾。將濾餅以冷丙酮(2χ25 ml)清洗並以氮氣乾燥以得到此標題之化合物CMR(1〇〇 MHz,
CDC13) 206·08, 176·47, 175.41,139 63, 124 〇〇, 94 89, 90.97, 47.08, 43.90, 42.36, 41.58, 41.G7, 38.93, 36.97, 35.16, 33.01, 32.42, 31.35, 29.10, 23.08, 22.98和 14.23 5 ; NMR (400 ΜΗζ, CDCl3)0.94,1.40,1.4-2.8*5.70;MS(CI,>iH3)m/e= 385 (P + H,100%) 〇 步驟2 ) 17 /5 -羥基-7 α -碳甲氧娠Ύυ)·二烯-3_酮_21-羧 酸、Τ -内酯9 (圖示I)。
將一 5a,17/S_ 二羥基氧娠 _9(n)jt_3-酮、7α;,2卜二羧 I、雙-r_ 内酯(50.0 g,〇13〇〇5 m〇les)和碳酸氫钾(16 92 g,0.1690 moles,1·30 當量)於丙酮(2〇〇 ml)和水(1〇〇 ml)中之 混合物於45 C下揽拌2小時,此時由液相層析lc完成5,7-内 酿(VII)轉化成叛酸(VI)之反應。形成之混合物之後經硫酸 二甲基(22.92 g,0.1817 moles,1.40當量),在 45°C 下攪拌 3小 時’之後先以碳酸氫鉀溶液〇 3 g,〇 〇i3〇 moles,〇」00當量) 在水中(10 ml)、接著以乾淨之三乙基胺〇 8ι以,H4 g, 0·0 130 mole,0.100當量)處理。將此混合物在45^下攪拌1小 84103-950628.doc -31 - 1280133 時,以濃縮之氫氯酸(1·92 ml,2·304 g,含有0.852 g (0.0234 moles,0·180當量)氫氯酸),冷卻至〇°C,在減壓下濃縮至體 積150 ml (罐溫13°C ),之後過濾並將濾餅以水(2x25 ml)清洗 並乾燥以得到此標題之化合物9 (圖示I )。 實例11 ·•依普利酮之形成。 如在美國專利號碼4,5 59,332和5,981,744,以及\¥〇97/21720 和W098/25948中之說明將二烯酮9 (圖示I )氧化以得到依 普利酮。 實例12 :三甲基矽烷基氰化物和I之晞丙化反應。 將一三醋酸酯I (表 1) (1.〇 g,2.24 mmol)於 10 mL CH2C12之 溶液冷卻至14°C並以0.6 mL TMSCN和100 mg Sc(〇Tf)3處 理。將此混合物攪拌5小時並以醋酸乙酯萃取,期間濃縮之 萃取結晶將從溶液中沉澱出來,將此些物質過濾並乾燥以 得到一腈18之異構物混合物。13C NMR(CDC13) δ 147.31, 146.0,131.68,129.39,128.12,119·23,115.47,115·〇4, 62·74, 82.50,51.13,49.0,47.72,44.38,43.67,43·05,37·32,37.04, 36.32,33.58,32.09,32.G,27.92,27.79,26·75,23.68, 23.32, 20.45, 19.13, 18.26, 12.30 〇 實例13 :烯丙基三甲基矽烷和ν之烯丙化反應 將一三醋酸酯V(表1)和烯丙基三甲基矽烷於乙腈中之溶液 以SC(〇Tf)3於室溫下處理。—小時後慢慢加水到沉殿產物 中,經過濾和乾燥產生烯丙基衍生物19。NMR(CD(:i3) 5 221.05,170.89,193.87,137.62,127·15,Ιΐ6·36,74 26 47.81,46.29, 38.61,37.49, 36.23, 35.61,35.31,3 1.57, 28 04 84103-950628.doc -32- 1280133 22.61,20.56, 19.64, 13.48。 實例14·•乙炔形成17-酮氧中間產物之加成作用。
步驟1 : 將穴曱基二石夕氮烷(HMDS)(l〇〇 ml)加至一含50.0 g三元醇1 之400 ml二氯甲烷之攪拌泥漿液中。加入糖精(〇·57 g)並於 回流下將混合物加熱3小時期間泥漿液將緩慢溶解成一清澈 號轴色落液。加水(5 ml)使任何過量之HMDS淬火。5分鐘後 將此混合物於回流下過濾流經一 35〇 ml粗陶瓷玻璃濾器漏斗 中含有32.6 g magnes〇kCII2Cl2濕層。此濾液應清澈且幾乎 無色。將此濾餅以1〇〇 ml CHAU清洗2次。結合之濾液於減 壓下濃縮並以蒸發方式利用2次5〇〇 ml之四氫呋喃(THF)除去 殘留之一氯甲坑’在各次加成之後濃縮至乾燥以得到一白 色固體。 步驟2 : 將一卜氧化丁基鉀(potassium t_bm〇xide)於500 ml THF中之懸 浮液利用一冰/甲醇浴冷卻至At ± 5t:。將乙炔打成氣泡 加入混合物之表面下並溫和攪拌至少1小時。將來自上面 THF(400 ml)中所得之矽烷化類固醇中間產物加入混合物中 超過30分鐘並於期間維持± 5之反應溫度。加成之 後,再於5 C ± 5 C之擺拌混合物一小時。緩慢加入水(丨〇〇 84103-950628.doc -33 - 1280133 ml)使反應混合物加溫至15°C ±5°C。緩慢加入125 ml 10% HC1以降低pH值至2.5至3。在溫度20°C ±5°C並於pH值2.5至3 下攪拌此混合物1至2小時,並視需要加入少量5% HC1以維 持pH值在2.5至3。當此水解反應完成後,加入半飽和之 NaHC03溶液以升高pH值至5.5至6。用醋酸乙酯(500 ml)稀釋 此混合物並且使之相分離。水相可利用醋酸乙酯萃取並用 水、鹽水清洗此結合之醋酸乙醋相,利用硫酸鍰乾燥並濃 縮得到加成產物 2。13C NMR(DMSO-d6) 5 141.99,127.38, 89·37, 77.73, 75,24, 72.13, 70.54, 67.68, 54.13, 49.57, 47.43, 43.94,42.58,40.52,40.22,39.01,38.09,31.95,25.8,18.58, 14.09。 實例15 :羥基乙醯化作用··
將四元醇11 (圖示II) (50.00 g,144 mmol)溶解在吡啶(150 ml)之混合物在冰浴中冷卻至低於10°C。加入二甲基胺基吡 啶(DMAP)(1.7 g,14 mmol)接著以一可維持溶液溫度低於10 °C之速度緩慢加入醋酸if (41.4 ml,439 mmol)。在加成反應 之後,將此反應混合物加溫至室溫。用醋酸乙酯(75 ml)和 水(50 ml)稀釋此混合物,攪拌5分鐘並使其相層分離。用 10% HCl(4x25 ml)清洗有機層,接著以H2O(2x50 ml)清洗, 84103-950628.doc -34- 1280133 以MgS04乾燥並濃縮。此產物以甲苯(100 ml)再結晶化。nC NMR(CDC13) δ 170.68, 170.10, 143.48, 128.90, 128.10, 125.17,122.59,86.63,78.21,75.07,74.40,72.79,71.47, 50.16, 48.07, 47.02, 38.76, 38.06, 37.83, 37.67, 36.92, 27.66, 24.18, 21.74, 21.44, 18.65, 13.06 ° 實例16 :乙炔加成物之氫甲醯化作用。
將一三醋酸酯 12 (圖示II) (25·4 g,54 mmol)、PPh3(2.13 g5 8.1 mmol)和 Rh2(OAc)4 (716 mg,1.62 mmol)於醋酸乙酯(200 ml)之溶液在80°C、利用氫/ 一氧化碳以1/1混合之170 psi壓 力加熱12小時。將此混合物於減壓下濃縮且利用管柱層析 法(70/3 0 EtOAc/Hex和5 00 g矽石)純化產物13 (圖示II)。此 化合物之CMR光譜由於開環和閉環異構物而變得很複雜並 且因此無法完全定性化。 實例17 ··乳酸-/3 -莕酯形成内酯之氧化反應。
84103-950628.doc 1280133 將一乳酸-召-莕酯4 (圖示I ) (25 g,50 mmol)、二氯甲燒 (250 ml)、水(38 ml)、2,2,6,6-四甲基旅啶-1-氧基 (TEMPO)(156 mg,1 mmol)、溴化钾(595 mg5 5 mmol)和 NaHC03(5.5 g5 65 mmol)之混合物在冰浴中冷卻至$l〇°C。緩 慢加入一 1·1 Μ之次氯酸鈉(NaOCl) (50 ml,55 mmol)溶液。 將此混合物加溫至室溫並以水(5 0 in 1)稀釋,使相層分離且 以鹽水(2x50 ml)清洗有機層。有機層以MgS04乾燥,過濾並 濃縮以產生5之一非白色泡沫。13c NMR(CDC13) δ 177.94, 172.60,172.15,171.58,145.49,124.36, 96.18,(79.22, 78.90, 78.59 CDC13),76·59, 74.57, 72.63, 52.14, 49·55, 47.75, 40.00, 39.75, 39.61,38.65, 37.47, 32·74, 30.85, 29.56, 26.01,23·61, 23.37, 23.17, 23.11,20.52, 16·19。 實例1 8 :呋喃化作用。
將一三醋酸酯14 (圖示I) (ι·3〇 g,2·58 mmol)、2-甲基呋喃 (0·8 mL)於25 mL乙腈中之溶液以250 mg Sc(OTf)3於20°C下 處理並攪拌1小時。此產物可利用EtOAc萃取液分離出來並 利用色層分析法以矽膠和40% EtOAc/Hex將之純化以得到 1·〇 g (74% 產量)之呋喃 15。13C NMR(CDC13) (5 176.27, 84103-950628.doc -36- 1280133 170.45, 169.85, 140.60, 123.45, 110.05, 45.40, 44.60, 38.55, 38.37, 31.81,30.72, 28.96, 28.93, 18.80, 14.83, 14.13, 14.06, 152·53,150.96. 1〇6.〇1,94.95, 73.39, 7ΐ 37 46 5〇 38.06, 37.78, 37.74, 36.89 35 41 ---〇7s2,63s2,74;2〇2 13.62 〇 ’ 實例19 :醋酸酯水解作用 〇
將一81〇 mg之二酷酸醋15 (圖示H) 、120 mg K2C〇3之混合 物在20 mL甲醇中於反應過程中攪拌隔夜。tlc顯示此反應 未完成因此加入額外之1〇〇 mg Κχ〇3並續攪拌直到tlc顯示 出儿成反應為止。將此混合物以HC1酸化且以EtOAc萃 取產物。在利用色層分析之矽膠和1〇〇%Et〇Ac產生61〇 mg(89.5〇/〇產量)之二元醇16 (圖示11:) 。13(: nmr(cdc13)占 176.68, 153.20, 150.79, 142.05, 122.32, 109.80, 105·94, 95.3, 71.83, 68.64,50.13, 45.81,44.88, 42·73, 42.62, 39.G1,38.56, 37.73,36.81,35.44,31.57,30.84,29.06,23.13,18.81,15.27, 13.64。 實例20 ·· 16形成Π之氧化反應。 84103-950628.doc -37- 1280133 ο
將二元醇16 (圖示II)溶解在2 mL甲苯和〇_ 1 mL丙酮中並以 50 mg aluminum isopropoxide處理並加熱至l〇〇°C。數小時之 後此將出現無轉化作用因此加入〇 ·丨mL環己酮並將混合物 加為隔伙。利用醋酸乙酯當成溶析液藉由矽膠層析法將產 物 17 (圖不Ιυ 分離出。13c NMR(CDC13)(5 199.96, 177.05, 170.32’ 153.34,150.74,126.7,109.14,106.33,95.54,69·〇8, 52.50,46.26,46.0,43.58,40.13,39.05,38.8,37.93,36.92, 35·66, 34,595 31·335 29,47, 23.G65 1 8,835 1 6.G1,13·90。 84103-950628.doc 38-
Claims (1)
- :r ,十如 請蛛利範圍 一種製備式I之7- Ml%修正 經取代類固醇化合物式I 其中1是11或一cor2 ·, 以2是<^-(:6烷基或是心-仏烷氧基; 0-^3 冗!是CH2或$ ’其中的〇汉3呈α組態; R3是 Η或-C0R2 ; Ζ2是-CH-;或 Ζι和Ζ2之間可能形成碳-礙雙鍵; Q 是〉Y是-CN、-CH2-CH=CH2、 其中RfOCu烷基;或 C(〇)r4 , 其包含將式類固醇中間產物與一親核劑在路易士酸 觸媒存在下反應 84103-950628.doc 1280133式II 其中R!和R3,Z1;> Z2,R2和Q如式I所示。 2. 一種式I之化合物, 其中1是11或一COR2 ; 化是心-匕烷基或是匕-匕烷氧基; ORj 冗1是(:112或一^一 ,其中的0R3呈α組態; R3是 Η或-C0R2 ; Z2是-CH-;或 Z!和Z2之間可能形成碳-碳雙键; Q是Y是-CN、-CH2- CH=CH2、一j完基 ’ ’或 c(o)r4, 其中RfOCw烷基。 3. —種製備依普利酮(eplerenone)之方法,其包含以下步 驟·· a)將式1之酮類固醇 84103-950628.doc -2- 1280133和匕-匕燒基氯甲酸醋或苄基 ^ T 酉旨或燒畜媒其贫二 唑,在三級有機鹼存在下進扣 ^ 二 境订反應,以產生式2之=破 酸酯其中尺是匕-匕烷基或苄基; A — &b)將式2之三,基化合物和2_ 燒基吱喃在路易士酸c)在驗存在下水解式3之二醯基酯化合物以產生式*之 二羥基酯; 觸媒存在下進行反應以產生式3之二醯酯化合物; 84103-950628.doc 1280133d)在強驗存在下將式4之化合物和乙块進行反應以產生 式5之炔類化合物;式5 e)在鍺觸媒配位子存在下將式XVII之炔類化合物和—# ^ 氣 化碳進行反應以產生式6之乳酸-/3 -莕酯; OH式6 f)氧化式6之乳酸-/3 -莕酯以產生式6a之内酯; 84103-950628.doc -4 - 1280133 ο式6a g)異構化式6a之4,5-雙键以產生式7之内酯;h)溴化、臭氧化、氧化和酯化式7之化合物以產生式8之 酯類; 〇式8 i)將式8之化合物進行脫水反應以產生式9之中間產物; 84103-950628.doc 1280133 όj)氧化式9之二晞酮於此將獲得依普利酮(式10)。 〇4. 一種式6a之化合物 〇5. —種製備依普利酮之方法,其包含以下步驟: a)將式1之酮類固醇84103-950628.doc -6- 1280133 和乙块進行反應以產生式11之化合物;式11 b)醯化式11之化合物以產生式12之化合物;12 c)氫曱基化式12之化合物以產生式13之化合物; OH13 d)氧化式13之化合物以產生式14之化合物;e)在路易士酸存在下將式14之化合物與2-烷基呋喃進行 接觸以產生式15之化合物; 84103-950628.doc 1280133 οf)水解式15之化合物以產生式16之化合物; 〇g)氧化式16之化合物以產生式17之化合物; 〇h)將式17化合物之呋喃環轉化成式18之甲基羰基化合 物; 〇i)將式18之化合物轉化成式19之磺酸酯; 84103-950628.doc 1280133 Ο19 j)移除式19之磺酸酯以產生式9之化合物;9 k)氧化式9之化合物以產生式10之化合物依普利酮; 〇6. —種如申請專利範圍第5項之製備依普利酮之方法,其 進一步包含式1化合物在其與乙炔反應前之矽烷化反 應,以產生一矽烷化中間產物,並除去在式11化合物的 分離期間之碎燒基。 84103-950628.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42448802P | 2002-11-07 | 2002-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200407151A TW200407151A (en) | 2004-05-16 |
TWI280133B true TWI280133B (en) | 2007-05-01 |
Family
ID=32312815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092106330A TWI280133B (en) | 2002-11-07 | 2003-03-21 | Process for preparing C-7 substituted steroids |
Country Status (19)
Country | Link |
---|---|
US (1) | US20040097475A1 (zh) |
EP (1) | EP1562974B1 (zh) |
JP (1) | JP2006508962A (zh) |
KR (1) | KR100667123B1 (zh) |
CN (1) | CN1694896A (zh) |
AT (1) | ATE354583T1 (zh) |
AU (1) | AU2003220139A1 (zh) |
BR (1) | BR0316052A (zh) |
CA (1) | CA2500580A1 (zh) |
DE (1) | DE60312029T2 (zh) |
ES (1) | ES2280739T3 (zh) |
HK (1) | HK1080088A1 (zh) |
MX (1) | MXPA05004024A (zh) |
PL (1) | PL376896A1 (zh) |
RS (1) | RS20050339A (zh) |
RU (1) | RU2289586C2 (zh) |
TW (1) | TWI280133B (zh) |
WO (1) | WO2004043986A1 (zh) |
ZA (1) | ZA200502698B (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235655B2 (en) * | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
CN1321128C (zh) * | 2005-07-15 | 2007-06-13 | 浙江医药股份有限公司新昌制药厂 | 孕甾-4-烯-7,21-二甲酸,9,11-环氧-17-羟基-3-氧代,γ-内酯,甲酯,(7α,11α,17α)-的制备方法 |
JP5130591B2 (ja) * | 2006-04-22 | 2013-01-30 | ハーバー セラピューティクス, インコーポレイテッド | 薬物および用途 |
CN101472579B (zh) * | 2006-04-22 | 2013-07-03 | 霍利斯-伊登医药公司 | 药物和用途 |
US8354396B2 (en) * | 2006-11-17 | 2013-01-15 | Harbor Therapeutics, Inc. | Drug identification and treatment method |
US20080221074A1 (en) * | 2006-11-17 | 2008-09-11 | Jaime Flores-Riveros | Drug Screen and Treatment Method |
US20080153792A1 (en) * | 2006-11-17 | 2008-06-26 | Frincke James M | Drug Identification and Treatment Method |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
US8486926B2 (en) * | 2006-11-17 | 2013-07-16 | Harbor Therapeutics, Inc. | Steroid tetrol solid state forms |
CA2724130C (en) * | 2008-06-06 | 2016-04-26 | Harbor Biosciences, Inc. | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds |
WO2010036822A1 (en) * | 2008-09-24 | 2010-04-01 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
US20100222315A1 (en) * | 2008-09-24 | 2010-09-02 | Harbor BioSciencs, Inc. | Patient populations and treatment methods |
US20100227841A1 (en) * | 2008-09-24 | 2010-09-09 | Harbor BioSciencs, Inc. | Patient populations and treatment methods |
CN103087139B (zh) * | 2011-11-08 | 2016-08-03 | 中国科学院上海药物研究所 | 一种坎利酮衍生物类甾体化合物、其制备方法及其在制备依普利酮中的用途 |
CN105753930A (zh) * | 2016-03-30 | 2016-07-13 | 北京万全德众医药生物技术有限公司 | 依普利酮的一种合成方法 |
CN110698529A (zh) * | 2019-11-19 | 2020-01-17 | 湖南新合新生物医药有限公司 | 一种依普利酮中间体△9,11烯酯的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069219A (en) * | 1976-12-27 | 1978-01-17 | G. D. Searle & Co. | 7ξ-(Alkoxycarbonyl)-6ξ-alkyl/halo-17-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactones and corresponding 21-carboxylic acids, their salts, and esters |
FI77669C (fi) * | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
US5227375A (en) * | 1990-02-08 | 1993-07-13 | Endorecherche, Inc. | Aromatase inhibitors |
US5237064A (en) * | 1992-05-20 | 1993-08-17 | Merck & Co., Inc. | Process for producing 7β-substituted-aza-5αandrostan-3-ones |
ATE365171T1 (de) * | 1995-12-11 | 2007-07-15 | Searle Llc | Verfahren zur herstellung einer epoxyverbindung |
ES2293944T3 (es) * | 1996-12-11 | 2008-04-01 | G.D. Searle Llc. | Procedimiento de epoxidacion. |
US6887991B1 (en) * | 1996-12-11 | 2005-05-03 | G. D. Searle & Company | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein |
US6716829B2 (en) * | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
-
2003
- 2003-03-21 WO PCT/US2003/007284 patent/WO2004043986A1/en active IP Right Grant
- 2003-03-21 EP EP03716433A patent/EP1562974B1/en not_active Expired - Lifetime
- 2003-03-21 MX MXPA05004024A patent/MXPA05004024A/es unknown
- 2003-03-21 ES ES03716433T patent/ES2280739T3/es not_active Expired - Lifetime
- 2003-03-21 AT AT03716433T patent/ATE354583T1/de not_active IP Right Cessation
- 2003-03-21 PL PL376896A patent/PL376896A1/pl not_active Application Discontinuation
- 2003-03-21 CN CNA038248697A patent/CN1694896A/zh active Pending
- 2003-03-21 TW TW092106330A patent/TWI280133B/zh not_active IP Right Cessation
- 2003-03-21 JP JP2004551389A patent/JP2006508962A/ja not_active Withdrawn
- 2003-03-21 BR BR0316052-1A patent/BR0316052A/pt not_active IP Right Cessation
- 2003-03-21 RU RU2005117372/04A patent/RU2289586C2/ru not_active IP Right Cessation
- 2003-03-21 DE DE60312029T patent/DE60312029T2/de not_active Expired - Fee Related
- 2003-03-21 CA CA002500580A patent/CA2500580A1/en not_active Abandoned
- 2003-03-21 KR KR1020057008024A patent/KR100667123B1/ko not_active IP Right Cessation
- 2003-03-21 US US10/392,945 patent/US20040097475A1/en not_active Abandoned
- 2003-03-21 RS YUP-2005/0339A patent/RS20050339A/sr unknown
- 2003-03-21 AU AU2003220139A patent/AU2003220139A1/en not_active Abandoned
-
2005
- 2005-04-04 ZA ZA200502698A patent/ZA200502698B/en unknown
- 2005-12-31 HK HK05112224.8A patent/HK1080088A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006508962A (ja) | 2006-03-16 |
MXPA05004024A (es) | 2005-06-08 |
WO2004043986A1 (en) | 2004-05-27 |
RU2005117372A (ru) | 2006-01-20 |
RU2289586C2 (ru) | 2006-12-20 |
TW200407151A (en) | 2004-05-16 |
DE60312029D1 (de) | 2007-04-05 |
AU2003220139A1 (en) | 2004-06-03 |
CN1694896A (zh) | 2005-11-09 |
ZA200502698B (en) | 2006-07-26 |
HK1080088A1 (zh) | 2006-04-21 |
CA2500580A1 (en) | 2004-05-27 |
PL376896A1 (pl) | 2006-01-09 |
BR0316052A (pt) | 2005-09-20 |
EP1562974A1 (en) | 2005-08-17 |
DE60312029T2 (de) | 2007-06-21 |
ATE354583T1 (de) | 2007-03-15 |
US20040097475A1 (en) | 2004-05-20 |
RS20050339A (sr) | 2007-08-03 |
ES2280739T3 (es) | 2007-09-16 |
KR20050084953A (ko) | 2005-08-29 |
EP1562974B1 (en) | 2007-02-21 |
KR100667123B1 (ko) | 2007-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI280133B (en) | Process for preparing C-7 substituted steroids | |
JPS5865299A (ja) | 3β,7β,15α―トリヒドロキシ―5―アンドロステン―17―オン又はその3、15―ジピバレート及びそれらの製造法 | |
NO131119B (zh) | ||
EP1985621A1 (en) | Process for production of steroids | |
KR20050028907A (ko) | 스테로이드의 c-17 스피롤락톤화 및 6,7 산화 | |
AU775831B2 (en) | Process for preparing 17alpha-acetoxy-11beta-(4-N,N-(dimethylamino)phenyl)-21- methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates | |
JP5430603B2 (ja) | ググルステロン及びググルステロールの製造方法 | |
US20110009615A1 (en) | Method for producing a steroid compound | |
KR100638776B1 (ko) | 7-카르복시 치환된 스테로이드의 제조 방법 | |
US20130123523A1 (en) | Methods for the preparation of etonogestrel and desogestrel | |
KR100639655B1 (ko) | 16α,17α-에폭시프레그네놀론으로부터4,17(20)-프로스타디엔-3,16-디온의 제조방법 및 이를제조하기 위한 중간체 | |
TW200525036A (en) | Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters | |
WO1995016699A1 (fr) | Derive de steroide | |
JP2004307390A (ja) | ステロイド化合物の製造方法 | |
CN101003560A (zh) | 甾体中间体及其用途 | |
KR20040039869A (ko) | 구굴스테론의 개선된 제조방법 및 이에 사용되는 중간체 | |
US4145357A (en) | Steroid derivatives and process for preparing the same | |
JP2016527213A (ja) | アビラテロン酢酸エステルの製造方法 | |
US4097477A (en) | Steroid compounds and processes thereof | |
US4446072A (en) | Process for degrading the 20-carboxyl group of Δ4-Steroid-20-carboxylic acids | |
JPH05178884A (ja) | (+)−エストロン誘導体の製造法 | |
CN116377008A (zh) | 一种醋酸四烯物的制备方法和甾醇脱氢酶 | |
JP2006056877A (ja) | ステロイド化合物の製造方法 | |
JPH0586045A (ja) | 3,4−二置換−シス−γ−ラクトンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |